Posted Jun. 7, 2012 at 1:37 p.m.
GSK
The first commercial sales of Horizant for PHN will trigger a $10 million milestone payment to XenoPort, the Santa Clara, California company that discovered Horizant and co-developed the drug with GSK.
GSK wins approval for drug to treat shingles pain
Post a comment
Print this blog postE-mail blog post
Share
GSK
The first commercial sales of Horizant for PHN will trigger a $10 million milestone payment to XenoPort, the Santa Clara, California company that discovered Horizant and co-developed the drug with GSK.
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 MedCity. All rights reserved.Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
Raleigh-based PRA International eyes public offering- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows
- Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
- Triangle politician tries to accelerate crowdfunding; bill passes first hurdle
- ChannelAdvisor seeks $80M, sets share target price for IPO
- IT job openings 28% below 2012 numbers, report shows